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Abstract
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Polypharmacy is a highly prevalent problem in older persons, and is challenging to assess and
improve due to variations in definitions of the problem and the heterogeneous methods of
medication review and reduction. The purpose of this review is to summarize evidence regarding
the prevalence and impact of polypharmacy in geriatric oncology patients and to provide
recommendations for assessment and management. Polypharmacy has somewhat variably been
incorporated into geriatric assessment studies in geriatric oncology, and polypharmacy has not
been consistently evaluated as a predictor of negative outcomes in patients with cancer. Once
screened, interventions for polypharmacy are even more uncertain. There is a great need to create
standardized interventions to improve polypharmacy in geriatrics, and particularly in geriatric
oncology. The process of deprescribing is aimed at reducing medications for which real or
potential harm outweighs benefit, and there are numerous methods to determine which
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medications are candidates for deprescribing. However, deprescribing approaches have not been
evaluated in older patients with cancer. Ultimately, methods to identify polypharmacy will need to
be clearly defined and validated, and interventions to improve medication use will need to be
based on clearly defined and standardized methods.
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INTRODUCTION

Author Manuscript

Polypharmacy is often described as a prescribing challenge, particularly in the care of older
patients with cancer and multiple comorbid conditions that interact in complex ways. There
are various definitions of polypharmacy, making it challenging to understand the scope and
impact of the problem. A 2008 review suggested that there are 24 distinct definitions of
polypharmacy in general use, encompassing concepts ranging from unnecessary or
inappropriate medication use to the use of excessive numbers of medications.1 The lack of a
consistent definition and understanding of polypharmacy creates confusion for clinicians,
educators, and researchers.2

Author Manuscript

While the use of many medications may be a good practice for the treatment of many
chronic conditions, polypharmacy in the context of care of the older patient generally refers
to inappropriate polypharmacy, focusing on the negative aspects of medication use. Taking
an increasing number of medications, using medications that are not indicated for existing
medical conditions, being exposed to drug-drug interactions, and taking medications that are
high risk and/or low benefit (so-called inappropriate medications) are all potential negative
aspects of polypharmacy.3 Among the other negative effects of polypharmacy are increased
risk of adverse drug reactions, functional decline and falls, delirium and cognitive
impairment, and in some studies, increased risk of hospitalization, healthcare utilization, and
mortality, and even underprescribing.4-7 The more medications a patient is taking, the more
likely a patient is to have an adverse drug event, experience a drug-drug interaction, to take a
potentially inappropriate medication, or to be nonadherent to one of the medications.8
However, as demonstrated in recent cohort studies of middle-aged and older adults,
polypharmacy may not always be inappropriate or indicative of poor quality care,
particularly in chronic conditions in which multiple medications are required to maintain
stable disease control, such as cardiovascular disease.9, 10

Author Manuscript

The simplest and most conventional definitions for polypharmacy are those based on the
number of medications a patient is taking. When assessing for polypharmacy, a review must
include an assessment of non-prescribed medications as well as herbal medicines and
supplements. The use of 5 or more medications regularly has been a frequently used
definition for polypharmacy. The advantage of such a definition is the replicability in
research settings and ease of use in clinical practice when screening patients for
polypharmacy.11 However, the disadvantage of applying such a definition in clinical settings
is that simple medication number disregards the harmful or beneficial aspects of each
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medication. Using an absolute number of medications to define polypharmacy does not
account for a clinician's determination that polypharmacy may be appropriate in some
instances, when making individualized prescribing decisions. This is particularly the case for
patients with multimorbidity in whom multiple treatments have clear benefits. While some
have defined “excessive polypharmacy” as a very high number of medications (such as 10 or
more regular medications), this definition may have excellent specificity but inadequate
sensitivity to apply as a screening tool for harmful medication use.12 Taking 5 or more
regular medications has been associated with falls, disability, and frailty in general geriatric
populations and in geriatric oncology, and thus has some justification as a reasonable cutpoint for polypharmacy based on the association with adverse outcomes in older
patients.13, 14 For example, the sensitivity and specificity for 5 or more medications and the
risk of falls is 75.7% and 44.5%, respectively; at a cut-point of 10 or more medications, the
sensitivity is 24.3% and specificity is 85.5%.14

Author Manuscript

The use of medications and the presence of polypharmacy are on the rise in the general
population. In the United States, 90% of adults 65 and older participating in the National
Health and Nutrition Examination Survey in 2011-2012 reported taking at least one
prescription in the prior 30 days, and 39% reported using 5 or more prescription drugs.15
Based on population registry data from Tayside, Scotland, 22.1% of all persons used 5 or
more drugs, and 24.0% of people 80 years and older were dispensed 10 or more drugs in
2010.16 An additional contributor to polypharmacy is the use of complementary and
alternative medicine, which is highly prevalent in many populations, including older patients
with cancer. Such medications contribute to the overall pill burden, cost, nonadherence to
conventional medications, and risk of drug-drug and drug-disease interactions.17

Author Manuscript
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Older patients with cancer are potentially at a higher risk of polypharmacy. Geriatric
oncology patients have a high burden of comorbidity, geriatric conditions, and disability, and
are likely to use multiple medications and to be more susceptible to adverse effects of
medications.18 Many may already meet the criteria for polypharmacy prior to the initiation
of cancer chemotherapy and supportive care therapies. Cancer-related therapy also adds to
the prevalence of polypharmacy because of the increased pill burden and regimen
complexity, all of which can lead to compromised cancer management plans, such as
treatment delays or premature treatment discontinuation due to toxicity or adverse drug
events. Furthermore, in patients with advanced cancer near the end of life, as goals of care
change to more palliative treatment, additional medications are added to control symptoms,
while few medications for comorbid conditions are stopped.19 It is uncertain whether the
geriatric oncology population is uniquely susceptible to polypharmacy, and whether specific
interventions need to be designed for this population. The purpose of this narrative review is
to summarize evidence regarding the prevalence and impact of polypharmacy and potentially
inappropriate medicine use in geriatric oncology patients and to provide recommendations
for assessment and management.
POLYPHARMACY AND OUTCOMES IN CANCER
Several studies have evaluated the prevalence of polypharmacy in older patients with cancer.
Depending on the definition of polypharmacy, 11% to 96% of older patients with cancer
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were exposed to polypharmacy.14, 20-26 Nightingale and colleagues found a prevalence of
84% for polypharmacy, which includes 43% of patients who met criteria for excessive
polypharmacy, or 10 or more medications.24 The mean number of medications was 9.23 and
this was prior to anticancer therapy initiation for most of the patients in the cohort.24 Other
studies have found that older patients with cancer take a median number of medications of 5
to 9.1.14, 25 In advanced cancer, patients take more medications, likely because additional
drugs are added for supportive care.27 In one chart review of 100 patients with advanced
cancer, 95% had polypharmacy in the week before death.28 In oncology settings, the
presence of polypharmacy has been associated with higher numbers of comorbidities,
increased use of inappropriate medications, worse performance status, frailty syndrome,
poor physical function and poor survival.24, 29, 30

Author Manuscript

Several studies in geriatric oncology that have looked at multiple risk factors for adverse
outcomes have identified the effect of polypharmacy (Table 1). As defined by medication
number, polypharmacy has been associated with postoperative complications and length of
stay.31, 32 Increased medication number has also been associated with chemotoxicity in
some studies, but not consistently.33, 34 Polypharmacy was not associated with treatment
decisions in one study,35 but was associated with an increased likelihood of receiving nonsurgical treatment in another study.36 In addition, many studies have found an association
with polypharmacy and adverse geriatric-specific outcomes. Medication number has been
associated with physical function, frailty, and delirium in studies including geriatric
oncology patients.29, 37, 38 A recently published meta-analysis of data from three phase II/III
studies in ovarian cancer found that polypharmacy was associated with overall grade III/IV
toxicity, hematological and nonhematological toxicities, but not associated with overall
survival.39

Author Manuscript

While there are few studies regarding outcomes, the existing evidence suggests that an
increased number of medications used in geriatric patients with cancer could increase the
risk of complications, chemotoxicity, and increases the risk of functional decline. However,
most existing studies have evaluated polypharmacy as a covariate or risk factor as part of a
larger exploration of many potential risk factors for adverse outcome. Ultimately,
implementing polypharmacy screening and intervention as part of routine practice will
require studies specifically designed to examine the impact of polypharmacy on outcomes in
older patients with cancer.
POTENTIALLY INAPPROPRIATE MEDICATION USE

Author Manuscript

Potentially inappropriate medications (PIMs) are largely referred to as medications lacking
evidence-based indications, medications with treatment risks that may outweigh their
benefits, medications that are significantly associated with adverse drug reactions, and those
that may potentially interact with other medications or other diseases.40 There have been a
few specific criteria developed for identification of PIMs, including the Beers criteria and
Screening Tool for Older People's Prescriptions (STOPP). The Beers criteria was originally
developed in 1991 as a list of drugs to avoid in older patients residing in nursing homes and
has since been updated for older patients 65 and older and revised multiple times by expert
panels, most recently in 2015. It is a list of more than 110 potentially problematic
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medications to avoid and more than 60 drug-disease combinations to avoid in older
people.41 The STOPP criteria is a list of 80 indicators for appropriate prescribing, including
drugs and doses to avoid as well as drug-disease combinations to avoid. STOPP was
developed in 2008 and updated in 2015.42 Another tool to identify inappropriate medication
use is the Medication Appropriateness Index (MAI),43 a list of 10 indicators for prescribing
that are applied to each medication on a patient's list. This tool is useful to identify factors
like drugs lacking indication, lacking effectiveness, or potentially increasing the risk of
harm. The National Comprehensive Cancer Network (NCCN) Older Adult Oncology
Guideline refers to the MAI,44 however, the MAI may be time-consuming to administer,
cumbersome for use in clinical settings, must be performed by a skilled clinician with
training, and does not address underprescribing.45 The NCCN guidelines also present a list
of specific medications which may be considered of particular concern to the geriatric
oncology population including sedatives, first generation anti-histamines and anti-emetic
drugs.44
In the general geriatric population, 12%-63% are exposed to PIMs, based on either the Beers
or STOPP criteria.46 Most studies evaluating PIMs in patients with cancer have used the
Beers criteria.20, 22, 23, 47-49 To date, one study has evaluated the prevalence of PIMs in
patients with cancer using both the Beers and the STOPP criteria in a senior adult oncology
ambulatory center in the US.24 The overall prevalence of PIMs was 51%, and was 38%
according to STOPP criteria and 40% according to the 2012 Beers criteria.24
OUTCOMES ASSOCIATED WITH POTENTIALLY INAPPROPRIATE MEDICATION USE

Author Manuscript

Very few studies have evaluated whether the use of inappropriate medications is associated
with adverse outcomes in geriatric oncology. In a study of 414 older patients in the general
population, the presence of both PIMs and polypharmacy combined had a statistically
significant positive correlation to increased hospital readmissions. PIM use alone, however,
was not found to be significantly related to readmissions.50 In a secondary analysis of a
prospective study of factors related to chemotherapy-related adverse events in 7 academic
medical centers, there was no association found between either polypharmacy or PIM use
and chemotherapy toxicity or hospitalization.26 Another study evaluating the impact of PIMs
on outcomes in patients with breast cancer receiving chemotherapy found no association
between PIM use and the composite outcome of emergency room visits, hospitalization or
death in 6 months.51

Author Manuscript

Despite the potential harms of PIMs, observational studies of emergency room visits and
hospitalizations due to adverse drug reactions (ADRs) have found that most of the
medication-related harm in older persons is not due to PIMs, but is in fact due to common
classes of medications not considered inappropriate, including anticoagulants, opioids,
antiplatelet agents, oral hypoglycemic drugs, insulin, and antiarrhythmic agents.52 However,
in the same secondary analysis of chemotherapy-related adverse events that found no
association with PIMs, there was no association between these 6 high risk medication
classes and adverse outcomes.26 There are a few possibilities for the lack of association
between PIM use and adverse outcomes in geriatric oncology: 1) there are too few studies to
date to show an association, and the studies that have been conducted have included
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heterogeneous populations with early stage and advanced cancer patients; 2) it is possible
that no association between PIMs and harm exists in geriatric oncology; 3) several
medications considered to be PIMs are also necessary supportive oncology drugs, and may
actually mitigate harm in older patients. (NCCN) Additionally, PIM criteria may be
inapplicable to the end of life oncology population, when preventative medications might be
considered inappropriate but PIMs (e.g., benzodiazepines) might be appropriate and
recommended.53
ADDRESSING POLYPHARMACY AS PART OF GERIATRIC ASSESSMENT
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A strategy to provide more appropriate, safe medication use in older patients with cancer
may need to go beyond simple medication number, PIMs, and high risk medications to
include a comprehensive evaluation of medication use and risk factors for ADRs. The
medication use process comprises a series of stages including prescribing, communicating
medication orders, dispensing, administering and monitoring. Because of this multi-stage
process, adequate patient-provider consultation time is needed to conduct comprehensive
medication assessments in order to identify all medication related problems. This
comprehensive medication assessment should be done periodically, especially with the
initiation or modification of the patient's oncologic management or when there are changes
in disease management, changes in clinical condition and/or during transitions of care.
During the visit, the provider should confirm medication indication (e.g. medicationcondition matching), dosage (e.g. dosages appropriate for renal and/or liver function),
duration, assess for drug duplication, drug-drug-, drug-disease interactions and adverse
effects; in addition, the patient's ability to read medication label directions and to manage
medications in an organized manner should be assessed. The provider should not only
consider the pharmacological properties of the medications, but should also consider the
patient's comorbidities, cancer prognosis, cognitive and functional status as well as social,
cultural and economic factors. In this way, the prescribing process encompasses the patient's
goals of care coupled with maintaining quality of life. A comprehensive medication review
is considered to be an integral part of the geriatric oncology assessment based on the NCCN
Older Adult Oncology guidelines.44 The guidelines recommend a comprehensive medication
assessment, which includes a thorough review of patients’ medications with subsequent
discontinuation of any nonessential medications and evaluation for drug interactions,
adverse effects, and patient adherence. Geriatric assessment (GA) is a compilation of various
validated tools to assess multiple domains in older adults and has been shown in prior
studies to influence decision-making and predict outcomes such as hospitalization and
treatment complications in older patients with cancer.35, 54 While the domains of GA include
a comprehensive assessment of functional status, nutrition, comorbidities, cognition, mental
health, and social supports, a clear method for the assessment of polypharmacy has not been
established.
In recent years, an increasing number of studies have incorporated the use of GA in older
adults with cancer.35, 36, 55 However, polypharmacy was not consistently included as part of
the GA, which may be due to studies showing mixed results in the correlation between
polypharmacy and various clinical outcomes, compared to strong correlations noted in other
GA domains such as comorbidities, functional and nutritional status.33, 56-59 For studies that
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did include medication assessment, the data was often analyzed and presented as number of
medications. For example, Joly at al. identified that 43% of older patients aged 65 or above
with normal Karnofsky performance status (80%-100%) reported taking 9 or more
medications.60 Some studies further characterized polypharmacy but the definition varies,
with the most common definition being the concurrent use of ≥ 5 medications.35, 36, 55

Author Manuscript

When polypharmacy is detected from GA, it is unclear whether interventions aimed at
reducing medication number are of benefit. Further, many recommended interventions made
through GA may not have adequate uptake by oncologists. Selected studies published since
2010 assessing polypharmacy and associated interventions are shown in Table 2. In the
ELCAPA study, geriatricians proposed to have the prescribed medication changed in 31% of
patients based on GA results but the percentage of uptake from the proposed medication
intervention as well as the benefits of the intervention were not reported.35 In a study by
Kalsi et al, GA interventions were shown to improve chemotherapy tolerance in older
patients aged 70 or above undergoing chemotherapy.61 In this population, 19% received
intervention to reduce unnecessary medications such as adjustment of anti-hypertensive
medications in over or undertreated patients. These interventions, however, vary across the
various studies and were not clearly defined. In addition, while different definitions of
polypharmacy account for variation in different studies, differences in the way medication
use is actually assessed may lead to significant variation in prevalence and impact on
outcomes.
DEPRESCRIBING AS A POTENTIAL INTERVENTION FOR POLYPHARMACY
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Deprescribing is defined as the “systematic process of identifying and discontinuing drugs in
instances in which existing or potential harms outweigh existing or potential benefits within
the context of an individual patient's care goals, current level of functioning, life expectancy,
values, and preferences.”62 While few studies have evaluated the positive outcomes of
deprescribing, several trials have evaluated the potential negative consequences of stopping
medications, including exacerbation of the underlying disease as well as drug withdrawal
syndromes.63 A systematic review of drug withdrawal trials found that the vast majority of
medications could be safely stopped without adverse events, with careful attention to slower
withdrawal and close monitoring when stopping cardiovascular drugs and psychotropic
agents.63 Studies evaluating the positive effects of deprescribing have shown a reduction in
overall medication number, reduction in the number of inappropriate medications, reduction
in hospital length of stay, association with global improvements in health, and improvements
or slower declines in quality of life.62 No studies have been specific to geriatric oncology
patients, and thus, the benefits and harms of deprescribing in geriatric oncology are
unknown.
Patients who are prescribed multiple drugs, who take potentially inappropriate medications
(PIMs), and who have changing goals of care are among the candidates for careful
medication review with a consideration of deprescribing where appropriate. The process of
deprescribing has been described in five steps (see Box).62 Some of the steps may seem
more straightforward and feasible in geriatric oncology. The ability to identify those drugs
that are high risk/low benefit and to prioritize their discontinuation remains an area in which
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further research is greatly needed, both in geriatric oncology and in general geriatric
populations.
Although deprescribing is a possible intervention for older patients with cancer who have
polypharmacy, the question remains who should lead this intervention among a team that
may consist of a geriatrician, oncologist, pharmacist, and primary care provider. Barriers to
accomplishing a deprescribing intervention include the oncologists’ familiarity and comfort
with making changes to non-cancer medications, the need for communication and
coordination with other providers, the patient or family member's reluctance to change
medication, and, of course, the lack of evidence of benefit or harm of deprescribing in this
population.

Author Manuscript

One approach to optimizing the prescribing and de-prescribing process is through utilization
of pharmacists as part of the healthcare delivery model for inter-professional, team-based
care.41 The Institute of Medicine recognizes the significant role played by pharmacists in the
areas of medication therapy management and medication safety, as well as the value of
pharmacist–physician collaboration in patient care.64-66 Pharmacists have the professional
education, training, skills, and medication use expertise to employ evidence-based medicine
which is crucial for this complex population that takes multiple medications. Teams led by
pharmacists to identify, prevent, and resolve medication related problems and promote the
correct use of medications may improve the likelihood that patients receive appropriate
pharmaceutical care.7 Thus, there is potential for pharmacists to play an important role as a
member of the inter-professional team.

CONCLUSIONS
Author Manuscript
Author Manuscript

In summary, there is a need for validated methods to define polypharmacy and to incorporate
assessment and evaluation as a standard part of GA for older adults with cancer. While there
are many acceptable definitions of polypharmacy, GA that includes screening for harmful
medication use may require a simplified approach, to be able to consistently define the
prevalence and impact of the problem and to design interventions. An increased number of
medications that a patient is regularly taking is the most significant independent predictor of
harm,62 both in general geriatric and in geriatric oncology populations. Once polypharmacy
has been screened, the next step is to use a combination of tools designed to identify harmful
medication use, such as the Beers and STOPP criteria, the MAI, as well as a review for high
risk drugs. The Beers, STOPP, and MAI are considered viable options for use in clinical
practice and may complement each other in their ability to identify harmful medications.
Once harmful medication use has been identified, deprescribing interventions need to be
initiated. Ultimately, to incorporate the assessment of polypharmacy into GA studies and
interventions, a clear, simple definition of polypharmacy would be beneficial, and the
methods of medication review and intervention need to be clearly described and developed
within the field to improve replicability of such studies.
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Box. Steps to Deprescribe62

Author Manuscript

1)

Reconcile all medications and consider their indications.

2)

Consider overall risk of harm when considering the intensity of
deprescribing intervention.

3)

Assess each drug in terms of current or future benefit in relation to current
or future harm.

4)

Prioritize drugs for deprescribing, giving preference to those that have the
most unfavorable risk/benefit ratio and least likelihood of withdrawal
symptoms.

5)

Implement a discontinuation plan and monitor for improvement or adverse
effects as the result of deprescribing.

(Adapted from Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al.
Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med.
2015;175(5):827-34.)
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Table 1

Author Manuscript

Polypharmacy and Association with Outcomes in Geriatric Oncology
Study

Population

Definition of Polypharmacy

Patients Meeting
Polypharmacy
Criteria
N

%

Outcomes

Author Manuscript
Author Manuscript

Caillet et al.
201135

375 patients ≥70 years with
solid tumors in a GA
intervention; 54.6% had
metastatic disease

≥5 oral medications daily

242

67%

Not associated with a change in
cancer treatment plan

Parks et al.
201536

47 women ≥70 years with
early stage, operable breast
cancer

≥4 daily medications

27

59%

Associated with non-surgical
treatment of cancer (p=0.002)

de Glas et al.
201331

3179 women ≥65 years who
underwent surgery for breast
cancer (all stages)

≥ 5 different types of medication

428

14%

Associated with the risk of
postoperative complications
OR 1.84, 95% confidence
interval (CI) 1.46-2.32

Badgwell et al.
201332

111 patients ≥65 years
undergoing abdominal surgery
for types of cancer, primarily
GI

Use of ≥ 5 medications

53

48%

Increased length of stay OR
2.45, 95% CI 1.09-5.49

Hamaker et al.
201433

73 women ≥65 years with
metastatic breast cancer
receiving first-line singleagent palliative chemotherapy

Use of ≥ 5 medications

37

51%

Associated with grade 3-4
chemotherapy-related toxicity
Unadjusted OR 6.38, 95% CI
1.99-23.47

Freyer et al.
200537

83 women >70 years with
Stage III/IV ovarian cancer

≥ 6 daily medications

7

8%

Lower overall survival
(p=0.04) for those with
polypharmacy

Kim et al.
201434

98 patients ≥65 years
receiving palliative
chemotherapy (multiple
cancer sites included)

>6 medications

39

40%

No association with early
discontinuation of palliative
chemotherapy

Turner et al.
201429

385 patients ≥ 70 years seen
in an outpatient oncology
clinic (multiple cancer sites
included)

Use of ≥ 5 regular medications

221

57%

Associated with impaired
physical function (OR 1.13,
95% CI 1.06-1.20) and being
frail (OR 4.48, 95% CI
1.90-10.54) and pre-frail (OR
2.35, 95% CI 1.43-3.86)

Senel et al.
201538

213 patients, mean age 60.3
years, in an inpatient palliative
care unit (multiple cancer sites
included)

Use of >3 medications

111

52%

Associated with incident
delirium in univariate analysis
(p<0.05)

Elliot et al.
201430

150 patients >60 years of age,
with acute myelogenous
leukemia (AML)

Use of ≥ 4 medications

78

52%

Associated with 30-day
mortality in adjusted analysis
(OR 9.98, 95% CI 1.18-84.13).
Lower odds of achieving
remission (OR 0.20, 95% CL
0.06-0.65)
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Table 2

Author Manuscript

Interventions for Polypharmacy in Geriatric Assessment Studies

Author Manuscript

Study

Definition of Polypharmacy

Interventions

Outcome

Aparicio et al.
201067

1 anticoagulant or 2 cardiovascular or 2
psychotropic medications or ≥10
medications

Geriatricians proposed nononcologic treatment adaptation

CGA led to an adaptation of the nononcological treatment in 15 (72%) and of
the social care in 8 (38%) patients, but
never modified the oncological strategy

Caillet et al.
201135

Concurrent use of >= 5 medications

Geriatricians proposed change in
prescribed medication

Functional status assessed by the ADL
score and malnutrition were
independently associated with changes in
cancer treatment

Horgan et al.
201268

--

Geriatric oncology service made
recommendations on medication
change

Previously unidentified medical problems
were identified in 70% of patients

Kalsi et al.
201561

Concurrent use of >= 5 medications

Intervention to reduce
unnecessary medications such as
adjustment of antihypertensive
medications in over or
undertreated patients

Geriatrician-led CGA interventions were
associated with improved chemotherapy
tolerance
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